NCT05396859View on ClinicalTrials.gov

Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 28, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Acute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
DRUG

Decitabine and Cedazuridine

Given PO

DRUG

Entrectinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

97239

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Taiho Oncology, Inc.

INDUSTRY

lead

OHSU Knight Cancer Institute

OTHER

NCT05396859 - Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter